Page 1

++ adapthealth FOR IMMEDIATE RELEASE ADAPTHEALTH CORP . ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS Plymouth Meeting , PA – August 5 , 2021 – AdaptHealth Corp. ( NASDAQ : AHCO ) ( “ AdaptHealth ” or the " Company " ) , a national leader in providing patient - centered , healthcare - at - home solutions including home medical equipment , medical supplies , and related services , announced today financial results for the second quarter ended June 30 , 2021 . Highlights • In the second quarter , AdaptHealth delivered its highest quarterly net revenue and adjusted EBITDA as a public company . • • • AdaptHealth completed four acquisitions during the quarter , including the previously announced acquisition of New England - based Spiro Health Services , a provider of home medical equipment and supplies , and Healthy Living Medical Supplies , a Michigan - based diabetes management business . AdaptHealth completed six additional acquisitions following the quarter , expanding HME operations in Kentucky , Ohio , West Virginia , New Jersey , New York , South Carolina , and Florida . To date , the Company has acquired over $ 300 million of annualized revenue in 2021 , incremental to AeroCare . Second Quarter Results • Net revenue was $ 617.0 million , compared to $ 232.1 million in the second quarter of 2020 , a 166 % increase . • Organic growth for the second quarter was 10.1 % . • . Net income attributable to AdaptHealth Corp. was $ 79.1 million , or $ 0.12 per diluted share , compared to $ 4.5 million , or $ 0.08 per diluted share , in the second quarter of 2020 . Adjusted EBITDA was $ 147.4 million , compared to $ 42.6 million in the second quarter of 2020 , a 246 % increase . • Adjusted EBITDA less Patient Equipment Capex was $ 98.9 million , compared to $ 30.6 million in the second quarter of 2020 , a 223 % increase . Increased Guidance Based on current business and market trends , the Company is increasing its previously issued financial guidance for fiscal year 2021 as follows : • · Net revenue of $ 2.38 billion to $ 2.48 billion , up from prior guidance of $ 2.22 billion to $ 2.39 billion ; Adjusted EBITDA of $ 555 million to $ 580 million , up from prior guidance of $ 525 million to $ 565 million ; and Adjusted EBITDA less Patient Equipment Capex of $ 360 million to $ 375 million , up from prior guidance of $ 330 million to $ 360 million .